Mirador Therapeutics
Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases.
$250M Series B+ ·
Source: Pulse 2.0
Total raised: $650M across 2 sourced rounds
All 2 rounds ↓Signals
About Mirador Therapeutics
The company uses its Mirador360 engine, which combines biology, multi-modal data, AI, and analytics, to identify targets and select therapies. Mirador Therapeutics aims to discover and develop precision medicines for patients with immuno-fibrotic diseases.
Mirador Therapeutics | 226 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $250M | — | Pulse 2.0 | |
| Series A | $400M | fiercebiotech.com |
Timeline
- Website created
Founders and team
MM
Mark McKenna FounderAL
Allison Luo Chief Medical OfficerGG
Gregg Gilbert CFOJZ
Jordan Zwick Chief Business OfficerMS
Maulik Shah Chief Financial OfficerNE
Nori Ebersole Chief People OfficerOL
Olivier Laurent Chief Scientific OfficerTA
Tim Andrews Chief Legal OfficerWS
William Sandborn Chief Strategy Officer
Investors
AAdage Capital Management
AAlexandria Venture Investments
AARCH Venture Partnerslead investor
FFairmount Funds Managementlead investor
FFarallon Capital Management
FFidelity
- FFidelity Management & Research Company
IInvus
LLogos Capital
OOrbiMedlead investor
PPoint72
PPoint72 Ventures
RRTW Investments
SSanofi Ventures
TT. Rowe Price
TTCG Crossover
WWoodline Partners
Companies like Mirador Therapeutics
EEngimmune Therapeutics$16M Seed · May 2022OOuro Medicines$120M Series A · Jan 2025
BBionyra$165M Series A · Jun 2026
SSudo Bio$37M Series A · Sep 2022OOrbital TherapeuticsSeries A · Aug 2025
CCitryll$92.5M Series B+ · Dec 2024
Other companies backed by ARCH Venture Partners
Bbit.bio$25M Series B+ · Nov 2026
SSoufflé Therapeutics$135M Series B+ · Oct 2026
OOratomic$475M Series B+ · Oct 2026
LLifeMine Therapeutics$75M Series B+ · Aug 2026
SSynchron$275M Series B+ · Jun 2026
LLightcast$27M Series B+ · Apr 2026
ARCH Venture Partners portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/mirador-therapeutics (get a free API key).